Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of α1 antitrypsin deficiency on lung volume decline in severe asthmatic patients undergoing biologic therapy.
Vianello A, Caminati M, Senna G, Arcolaci A, Chieco-Bianchi F, Ferrarotti I, Guarnieri G, Molena B, Crisafulli E. Vianello A, et al. Among authors: chieco bianchi f. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1414-1416. doi: 10.1016/j.jaip.2020.12.061. Epub 2021 Jan 10. J Allergy Clin Immunol Pract. 2021. PMID: 33440256 No abstract available.
Omalizumab management beyond clinical trials: the added value of a network model.
Caminati M, Senna G, Chieco Bianchi F, Marchi MR, Vianello A, Micheletto C, Pomari C, Tognella S, Savoia F, Mirisola V, Rossi A; NEONET Study Group. Caminati M, et al. Pulm Pharmacol Ther. 2014 Oct;29(1):74-9. doi: 10.1016/j.pupt.2014.01.007. Epub 2014 Feb 6. Pulm Pharmacol Ther. 2014. PMID: 24508951
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.
Caminati M, Senna G, Stefanizzi G, Bellamoli R, Longhi S, Chieco-Bianchi F, Guarnieri G, Tognella S, Olivieri M, Micheletto C, Festi G, Bertocco E, Mazza M, Rossi A, Vianello A; North East Omalizumab Network study group. Caminati M, et al. BMC Pulm Med. 2016 Aug 25;16(1):128. doi: 10.1186/s12890-016-0290-5. BMC Pulm Med. 2016. PMID: 27562427 Free PMC article. Review.
Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life Perspective.
Caminati M, Vianello A, Chieco Bianchi F, Festi G, Guarnieri G, Marchi MR, Micheletto C, Olivieri M, Tognella S, Guerriero M, Senna G; NEONET Study Group. Caminati M, et al. J Investig Allergol Clin Immunol. 2020;30(1):35-41. doi: 10.18176/jiaci.0379. Epub 2019 Jan 24. J Investig Allergol Clin Immunol. 2020. PMID: 30676321 Free article.
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey.
Matucci A, Caminati M, Vivarelli E, Vianello A, Micheletto C, Menzella F, Crisafulli E, Passalacqua G, Bagnasco D, Lombardi C, Parronchi P, Crivellaro MA, Chieco-Bianchi F, Rita Marchi M, Guarnieri G, Cosmi L, Rossi O, Almerigogna F, Senna G, Vultaggio A. Matucci A, et al. Among authors: chieco bianchi f. Allergy. 2021 Mar;76(3):871-874. doi: 10.1111/all.14516. Epub 2020 Aug 11. Allergy. 2021. PMID: 32716580 No abstract available.
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity.
Caminati M, Vultaggio A, Matucci A, Senna G, Almerigogna F, Bagnasco D, Chieco-Bianchi F, Cosini F, Girelli D, Guarnieri G, Menzella F, Micheletto C, Olivieri O, Passalacqua G, Pini L, Rossi O, Vianello A, Vivarelli E, Crisafulli E. Caminati M, et al. Among authors: chieco bianchi f. Respir Med. 2021 Jan;176:106261. doi: 10.1016/j.rmed.2020.106261. Epub 2020 Nov 26. Respir Med. 2021. PMID: 33260107 Free PMC article.
31 results